Persistent psychosis after reduction in pre- and post-synaptic dopaminergic function

J Neural Transm Gen Sect. 1994;95(1):49-61. doi: 10.1007/BF01283030.

Abstract

The purpose of this study was to evaluate the hypothesis that neuroleptic non-response in the face of "adequate" DA post-synaptic receptor blockade reflects failure of regulatory mechanisms to decrease DA pre-synaptic activity. Eight chronic schizophrenics, meeting rigorous criteria for neuroleptic non-response, were treated for four weeks with alpha-methylparatyrosine as an adjunct to their previously stable neuroleptic dose. Treatment with AMPT produced a prompt decrease in plasma HVA that was, on average, 72% lower at the end of the study. While there was also strong clinical evidence of reduction in central dopaminergic activity (both a significant reduction in dyskinetic movements and increase in extrapyramidal symptoms), there was virtually no change in severity of psychotic symptoms. Thus, in this group of non-responders, psychotic symptoms persisted despite both extensive dopamine post-synaptic receptor blockade and marked reduction of presynaptic activity. These symptoms may not be directly DA dependent.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Antipsychotic Agents / adverse effects
  • Antipsychotic Agents / pharmacology
  • Antipsychotic Agents / therapeutic use
  • Basal Ganglia Diseases / chemically induced
  • Dopamine / biosynthesis
  • Dopamine / physiology*
  • Drug Resistance
  • Drug Synergism
  • Frontal Lobe / physiopathology
  • Homovanillic Acid / blood
  • Humans
  • Male
  • Methyltyrosines / pharmacology
  • Methyltyrosines / therapeutic use*
  • Middle Aged
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Receptors, Dopamine / drug effects
  • Receptors, Dopamine / physiology
  • Schizophrenia / blood
  • Schizophrenia / drug therapy*
  • Schizophrenia / physiopathology
  • Schizophrenic Psychology*
  • Severity of Illness Index
  • Treatment Failure
  • Tyrosine 3-Monooxygenase / antagonists & inhibitors
  • alpha-Methyltyrosine

Substances

  • Antipsychotic Agents
  • Methyltyrosines
  • Nerve Tissue Proteins
  • Receptors, Dopamine
  • alpha-Methyltyrosine
  • Tyrosine 3-Monooxygenase
  • Dopamine
  • Homovanillic Acid